Provided by Tiger Fintech (Singapore) Pte. Ltd.

Moleculin Biotech

0.9978
-0.0222-2.18%
Volume:109.34K
Turnover:106.80K
Market Cap:13.97M
PE:-0.16
High:1.03
Open:1.03
Low:0.9374
Close:1.02
Loading ...

BRIEF-Moleculin Announces New Pre-Clinical Data For Annamycin

Reuters
·
29 Apr

Moleculin Announces New Pre-Clinical Data for Annamycin Demonstrating Market Expansion Potential Including Treatment for Pancreatic Cancer

THOMSON REUTERS
·
29 Apr

Moleculin Announces New Pre-Clinical Data for Annamycin Demonstrating Market Expansion Potential Including Treatment for Pancreatic Cancer

GlobeNewswire
·
29 Apr

Moleculin Biotech Releases Corporate Presentation Online

TIPRANKS
·
22 Apr

Moleculin Biotech’s Annamycin Highlighted at AACR 2025

TIPRANKS
·
17 Apr

BRIEF-Moleculin Announces Acceptance Of Abstract To Be Presented At The American Association For Cancer Research Annual Meeting 2025

Reuters
·
17 Apr

Moleculin Announces Acceptance of Abstract to Be Presented at the American Association for Cancer Research (Aacr) Annual Meeting 2025

THOMSON REUTERS
·
17 Apr

Moleculin Biotech doses first patient in Phase 3 MIRACLE trial

TipRanks
·
02 Apr

BRIEF-Moleculin Doses First Patient In Pivotal, Adaptive Phase 3 Miracle Trial

Reuters
·
01 Apr

Moleculin Biotech Inc - Preliminary Data From First 45 Subjects Expected in H2 2025

THOMSON REUTERS
·
01 Apr

Moleculin Doses First Patient in Pivotal, Adaptive Phase 3 Miracle Trial

THOMSON REUTERS
·
01 Apr

Moleculin Doses First Patient in Pivotal, Adaptive Phase 3 MIRACLE Trial

GlobeNewswire
·
01 Apr

All You Need to Know About Moleculin Biotech (MBRX) Rating Upgrade to Buy

Zacks
·
27 Mar

Moleculin Biotech Raised to Buy From Hold by Maxim Group

Dow Jones
·
25 Mar

Maxim Upgrades Moleculin Biotech to Buy From Hold, Price Target is $4

MT Newswires Live
·
25 Mar

Moleculin Biotech Inc : Maxim Group Raises to Buy From Hold

THOMSON REUTERS
·
25 Mar

Moleculin Biotech Inc (MBRX) Q4 2024 Earnings Call Highlights: Promising Clinical Trials and ...

GuruFocus.com
·
25 Mar

Q4 2024 Moleculin Biotech Inc Earnings Call

Thomson Reuters StreetEvents
·
25 Mar

Moleculin Biotech Advances Clinical Trials Amid Financial Losses

TIPRANKS
·
25 Mar

Moleculin Biotech Price Target Maintained With a $8.00/Share by HC Wainwright & Co.

Dow Jones
·
25 Mar